Published in Vaccine Weekly, June 22nd, 2005
In the June issue of the open-access journal PloS Biology, the team describes how a protein called lexA in the bacterium Escherichia coli promotes mutations and helps the pathogen evolve resistance to antibiotics. The scientists also show that E. coli evolution could be halted by subjecting the bacteria to compounds that block lexA. Interfering with this protein renders the bacteria unable to evolve resistance to the common antibiotics ciprofloxacin and rifampicin.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly